Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-17-000005
Filing Date
2017-05-08
Accepted
2017-05-08 15:09:55
Documents
6
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 2017 FIRST QUARTER REPORT firstquarter20176-k.htm 6-K 22802
2 2017 FIRST QUARTER INTERIM FINANCIAL STATEMENTS ex991interimfinancialstate.htm EX-99.1 300702
3 2017 FIRST QUARTER MD&A ex992-q12017mda.htm EX-99.2 166659
4 apc2.jpg GRAPHIC 60140
5 ittgroup.jpg GRAPHIC 42148
6 oncylogoa04.jpg GRAPHIC 32654
  Complete submission text file 0001129928-17-000005.txt   671748
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 000-31062 | Film No.: 17821924
SIC: 2834 Pharmaceutical Preparations